Lyn Baranowski has joined Roivant company Altavant Sciences as Chief Operating Officer.
Altavant is focussed on the clinical development of novel therapies aimed at pulmonary arterial hypertension and other indications.
Ms Baranowski joins from Melinta Theraputics where she served as Senior Vice President of Corporate Development and Strategy.
In this capacity, she helped guide the company through several important milestones including Melinta’s first FDA approval.
In her new position, Ms Baranowski will be involved in the general management of the company, leading cross-functional teams to establish and execute on a business and financing strategy that will deliver on the company’s short- and long-term business objectives.
“Ms. Baranowski’s strong record is matched by her passion and energy for building biotech companies,” said Altavant CEO William T. Symonds.
“She brings deep expertise in the execution of strategic financial and corporate transactions from her past career in biopharma and at venture capital firms.
“I look forward to leveraging her expertise as we grow Altavant and advance our pipeline including rodatristat ethyl.”